Building An Innovative And Streamlined Approach To End-To-End Regulatory eSubmissions
This article was originally published in SRA
Executive Summary
Organizations working in the pharmaceutical sector need to take action now to ensure that they have internal processes and systems in place that allow them to be compliant with rapidly evolving global regulatory requirements, particularly the growing use of electronic submissions by the major world regulators, says Darryl Clarke.
You may also be interested in...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.